Understanding the Impact of GLP-1 Inhibitors on the Food Away from Home Industry

As the use of GLP-1 inhibitors like Ozempic, Wegovy, and Mounjaro grows across the United States, their impact is beginning to reshape consumer behavior—especially when it comes to dining habits. IFMA The Food Away from Home Association's newest research report from the Consumer and Operator Research Group provides a data-driven, industry-focused analysis of awareness and usage patterns of GLP-1 medications, and what this means for the future of food consumption outside the home.

This first-of-its-kind study explores:

• Consumer Awareness and Adoption Trends of GLP-1 inhibitors
• Demographic Profiles of typical users—including age, income, and gender
• Behavioral Shifts in Dining Habits, portion preferences, frequency of dining out, and food choices

Whether you are a foodservice supplier, or an operator, this report offers critical insights into a rapidly changing landscape, where appetite suppression, wellness priorities, and healthcare innovations are influencing every aspect of the dining experience.

Why this matters:

GLP-1 inhibitors are not just a pharmaceutical trend—they are a cultural shift with direct consequences for sales volumes, menu planning, and consumer engagement across the FAFH sector. Understanding this shift now will allow your business to stay ahead of evolving customer expectations.

2025 GLP-1 Medication